A $3.3 million grant from the National Institutes of Health will help researchers at NC State investigate the molecular ...
September is Gynecological Cancer Awareness Month. Each Wednesday during the month, the coalition is hosting a free webinar ...
SurvivorNet on MSN
Beyond the Pink author Dr. Eleonora Teplinsky on the rising rates of young women with breast cancer and the support they need
'Beyond the Pink' was written to give patients relatable stories, practical support, and representation — including for women ...
UAE experts urge women to treat abnormal bleeding as a cancer red flag Uterine cancer can be difficult to recognise because some of its warning signs can easily be mistaken for ordinary hormonal ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. Keytruda significantly improved ...
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met ...
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met ...
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). And now, after meeting ...
May 18 (Reuters) - Merck (MRK.N), opens new tab said on Monday its experimental drug helped certain patients with uterine cancer live longer and kept their disease from worsening in a late-stage ...
TroFuse-005 demonstrated statistically significant, clinically meaningful OS and PFS gains with sac-TMT versus doxorubicin or paclitaxel in post-platinum, post–PD-1/PD-L1 endometrial ...
A breast cancer drug could provide new options for people suffering from treatment-resistant uterine cancer, according to new Yale School of Medicine (YSM) research. Uterine cancer is the deadliest ...
Overall, 91% of patients agreed that they would like to know about treatment options besides chemotherapy. Patients with endometrial cancer want an individualized, collaborative approach to their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results